Pancytopenia with aplastic anemia in systemic lupus erythematosus: case series and literature review.
Zaid Al-GhazawiAmwaj Al-FarajatAhmad A ToubasiHind B Abu TawilehAya QteishTariq N Al-AdilyFatima AlnaimatPublished in: Rheumatology international (2024)
Aplastic anemia (AA) is a rare, potentially catastrophic hematopoiesis failure manifested by pancytopenia and bone marrow aplasia. AA occurrence in Systemic Lupus Erythematosus (SLE) patients is extremely rare. The diagnosis may be delayed due to other possible pancytopenia etiologies. Confirmation of peripheral cytopenias diagnosis necessitates a bone marrow aspiration. The management of AA is challenging, and the literature reported using glucocorticoids, danazol, plasmapheresis, cyclophosphamide, intravenous immunoglobulin, and cyclosporine. We report two cases of SLE patients who presented with pancytopenia, with bone marrow biopsy confirmed AA. One case was treated with cyclophosphamide but unfortunately succumbed to Acute Respiratory Distress Syndrome (ARDS), while the other case was managed with rituximab with a good response. Interestingly, both patients were on azathioprine before the diagnosis of AA. A comprehensive search for reported cases of AA in PubMed, Scopus, and the Directory of Open Access Journals databases was performed to enhance the understanding of the diagnostic and management challenges associated with AA in SLE, facilitating ongoing exploration and research in this field. The decision to do a BM aspiration and biopsy is recommended for SLE patients with an abrupt decline in blood counts and previously stable blood counts.
Keyphrases
- bone marrow
- acute respiratory distress syndrome
- systemic lupus erythematosus
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- mesenchymal stem cells
- ultrasound guided
- extracorporeal membrane oxygenation
- disease activity
- high dose
- low dose
- prognostic factors
- systematic review
- peritoneal dialysis
- mechanical ventilation
- randomized controlled trial
- risk assessment
- minimally invasive
- acute lymphoblastic leukemia
- deep learning
- big data